Ropivacaine 0.2% for LFCB — Competitive Intelligence Brief

Ropivacaine 0.2% for LFCB (Ropivacaine 0.2% for LFCB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic (amide). Area: Anesthesia.

marketed Local anesthetic (amide) Voltage-gated sodium channels Anesthesia Small molecule

Target snapshot

Ropivacaine 0.2% for LFCB (Ropivacaine 0.2% for LFCB) — Poznan University of Medical Sciences. Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ropivacaine 0.2% for LFCB TARGET	Ropivacaine 0.2% for LFCB	Poznan University of Medical Sciences	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Buffered Lidocaine	Buffered Lidocaine	University of California, San Diego	marketed	Local anesthetic	Voltage-gated sodium channels
Bupivacaine liposomal injectable suspension	Bupivacaine liposomal injectable suspension	The University of Texas Health Science Center, Houston	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Bupivacaine + nalbuphine	Bupivacaine + nalbuphine	Alzahraa Ahmed Abbas	marketed	Local anesthetic + mixed opioid agonist-antagonist	Voltage-gated sodium channels (bupivacaine); kappa and mu opioid receptors (nalbuphine)
Ropivacaine + Midazolam	Ropivacaine + Midazolam	Aga Khan University	marketed	Local anesthetic + benzodiazepine combination	Voltage-gated sodium channels (ropivacaine); GABA-A receptors (midazolam)
Bupivacaine standard dose	Bupivacaine standard dose	Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Lidocaine + Prilocaine	Lidocaine + Prilocaine	Galeno Desenvolvimento de Pesquisas Clínicas	marketed	Local anesthetic	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic (amide) class)

1. Poznan University of Medical Sciences · 4 drugs in this class
2. Nantes University Hospital · 3 drugs in this class
3. Bozyaka Training and Research Hospital · 2 drugs in this class
4. ASST Gaetano Pini-CTO · 2 drugs in this class
5. Centre Hospitalier Universitaire de Nīmes · 1 drug in this class
6. Chiang Mai University · 1 drug in this class
7. Beijing Tiantan Hospital · 1 drug in this class
8. Complejo Hospitalario Universitario de Granada · 1 drug in this class
9. Ciusss de L'Est de l'Île de Montréal · 1 drug in this class
10. China Medical University, China · 1 drug in this class